Fresenius acquires assets from Hema Metrics

Fresenius Medical Care has acquired all assets of Hema Metrics LLC related to its Crit-Line system for an undisclosed amount. The deal includes all assets related to blood monitoring systems and the Crit-Line sales force, Mass Device reports. The Crit-Line system and its associated products are FDA 510(k) cleared and carry the CE mark.

According to its website, Salt Lake City-based Hema Metrics serves thousands of patients worldwide and provides products for more than 1 million treatments each year. Its Crit-Line III is a fluid management and access monitoring tool incorporating the latest photo-optical technology to non-invasively measure absolute hematocrit, percent blood volume change, continuous oxygen saturation and access recirculation.

The buy comes less than a month after Fresenius moved to challenge NxStage Medical in the home dialysis market, as Mass Device points out. Fresenius says it intends to establish this newly acquired technology as the standard of care for fluid and anemia management in the North American market. It adds the Crit-Line system is an excellent fit with Fresenius Medical Care North America's 2008K, 2008K2, and 2008T hemodialysis machines.

- get the Fresenius Medical Care release
- check out the Mass Device report

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.